All In Biotech

Drug Trial Radar · NCT01533220

Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal

A Randomized, Double-blind, Prospective, Multicentric, Superior Efficacy and Safety of Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal Due to Colds or Other Upper Respiratory Allergies

Last checked: Nov 19, 2026Latest source record: Jan 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

132

Actual

Start

Jan 1, 2013

Primary completion

Aug 31, 2013

Study completion Apr 30, 2014

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Feb 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The common cold is a major cause of nasal obstruction and reaches children and adults two or more times a year. At the moment, there is no cure for the common cold, and therefore the reduction of symptoms is the focus of the treatment. The study has parallel distribution design, with two equal groups, in which one group will be treated by a combination of naphazoline hydrocloride + pheniramine maleate + panthenol and the other will receive treatment with naphazoline hydrocloride.

Conditions

  • Flu
  • Cold
  • Allergic Disorder of Respiratory System

Interventions

  • naphazoline hydroclorideDrug

    02 drops into each nostril, 04 times a day for 03 days

  • Naphazoline hydrocloride + Pheniramine Maleate + PanthenolDrug

    02 drops into each nostril each 12 hours for 03 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of treatment in nasal congestion reduction based on Peak Flow Nasal Inspiratory (PFNI) assayTime frame: 3 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.